• Bleeding disorders

Bleeding disorders:

Indications for WILATE:

On-demand treatment and control of bleeding episodes in patients with von Willebrand disease (VWD) or hemophilia A. Perioperative management of bleeding in patients with VWD. Routine prophylaxis to reduce the frequency of bleeding episodes in patients with hemophilia A.

Adults and Children:

Give by IV injection at 2–4mL/min. VWD (<5yrs): contact manufacturer; (≥5yrs): Minor bleed: 20–40 IU/kg once, then 20–30 IU/kg every 12–24 hours as needed. Major bleed: 40–60 IU/kg once, then 20–40 IU/kg every 12–24 hours as needed. Surgery (give loading dose within 3hrs before); Minor: 30–60 IU/kg once, then 15–30 IU/kg (or half the loading dose) every 12–24 hours; Major: 40–60 IU/kg once, then 20–40 IU/kg (or half the loading dose) every 12–24 hours. Monitor and adjust according to VWF:RCo and FVIII activity, and location of bleed; usual treatment duration is 3 days (minor hemorrhage, minor surgery), 5–7 days (major hemorrhage), or ≥6 days (major surgery). Hemophilia A (<12yrs): contact manufacturer; (≥12yrs): Minor bleed: 30–40 IU/kg every 12–24 hours for ≥1 day. Moderate bleed: 30–40 IU/kg every 12–24 hours for ≥3–4 days. Major bleed: 35–50 IU/kg every 12–24 hours for ≥3–4 days. Life-threatening: 35–50 IU/kg every 8–24 hours until resolved. Routine prophylaxis: 20–40 IU/kg every 2–3 days. Monitor and adjust according to severity of deficiency/hemorrhage, desired FVIII level, presence of inhibitor. See full labeling.

Warnings/Precautions:

Treatment should be supervised by physician trained in coagulopathies. Risk of thrombotic events in VWD with sustained excessive FVIII levels; monitor. Ineffectiveness may indicate antibody formation (esp. for VWD type 3 patients); monitor; consider alternatives if confirmed. Risk of transmission of blood-borne diseases; consider vaccination against hepatitis A and B. Monitor pulse during injection; slow or stop infusion if marked increase in heart rate occurs. Pregnancy. Nursing mothers.

Pharmacologic Class:

Coagulation factor complex.

Adverse Reactions:

Urticaria, dizziness, pyrexia, hypersensitivity reactions (monitor); antibody formation.

How Supplied:

Kit—1 (w. diluent, supplies)